Search

Your search keyword '"Willlis H. Navarro"' showing total 2 results
Start Over Author "Willlis H. Navarro"
2 results on '"Willlis H. Navarro"'

1. Myelodysplastic syndromes clinical practice guidelines in oncology

Author

Peter L, Greenberg, Maria R, Baer, John M, Bennett, Clara D, Bloomfield, Carlos M, De Castro, H Joachim, Deeg, Marcel P, Devetten, Peter D, Emanuel, Harry P, Erba, Eli, Estey, James, Foran, Steven D, Gore, Michael, Millenson, Willlis H, Navarro, Stephen D, Nimer, Margaret R, O'Donnell, Hussain I, Saba, Kathy, Spiers, Richard M, Stone, and Martin S, Tallman

Subjects
Treatment Outcome, Myelodysplastic Syndromes, Anemia, Refractory, Hematopoietic Stem Cell Transplantation, Humans, Antineoplastic Agents, Leukemia, Myelomonocytic, Chronic, Erythrocyte Transfusion, Combined Modality Therapy, Algorithms
Published
2006

2. Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology

Author

Martin S. Tallman, Eli Estey, Stephen D. Nimer, Maria R. Baer, Kathy Spiers, Hussain I. Saba, Margaret R. O'Donnell, Peter L. Greenberg, Peter D. Emanuel, Carlos M. de Castro, Michael Millenson, James M. Foran, Richard Stone, H. Joachim Deeg, Marcel P. Devetten, John M. Bennett, Clara D. Bloomfield, Harry P. Erba, Willlis H. Navarro, and Steven D. Gore

Subjects
Oncology, medicine.medical_specialty, Myeloid, Anemia, business.industry, Myelodysplastic syndromes, medicine.medical_treatment, Chronic myelomonocytic leukemia, Myeloid leukemia, Hematopoietic stem cell transplantation, medicine.disease, medicine.anatomical_structure, Dysplasia, International Prognostic Scoring System, hemic and lymphatic diseases, Internal medicine, medicine, business
Abstract

The myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with relatively heterogeneous spectrums of presentation. The major clinical problems in these disorders are morbidities caused by patients' cytopenias and the potential for MDS to evolve into acute myeloid leukemia (AML). Managing MDS is complicated by the generally advanced age of the patients (median ages range from 65–70 years), the attendant non-hematologic comorbidities, and older patients' relative inability to tolerate certain intensive forms of therapy. In addition, when the illness progresses into AML, these patients experience lower response rates to standard therapy than patients with de novo AML. For the most recent version of the guidelines, please visit NCCN.org

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results